New therapy targeting heart failure mechanisms
PP2A Anchoring Disruptor Therapy in Heart Failure
This study is exploring a new way to help people with heart failure by looking at how certain proteins in heart cells work together, and it hopes to improve heart function for patients who are dealing with this condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cardiac Rsk3 Inhibitors, LLC NIH-funded |
| Lab location | 1 site (Los Altos, United States) |
| Project ID | NIH-10687238 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic approach to treat heart failure by targeting specific protein complexes involved in cardiac remodeling. The study focuses on the role of a protein called mAKAPβ and its interaction with protein phosphatase 2A (PP2A) in heart cells. By disrupting these interactions, the research aims to improve heart function and reduce the progression of heart failure. Patients with heart failure or those at risk may benefit from this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with dilated cardiomyopathy or other forms of heart failure.
Not a fit: Patients with heart failure due to ischemic causes may not benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and quality of life for patients suffering from heart failure.
How similar studies have performed: While this approach is innovative, previous research has shown promise in targeting similar molecular pathways for heart failure treatment.
Where this research is happening
Los Altos, United States
- Cardiac Rsk3 Inhibitors, LLC — Los Altos, United States (Active)
Researchers
- Principal investigator: Cividini, Federico — Cardiac Rsk3 Inhibitors, LLC
- Study coordinator: Cividini, Federico
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.